Polskie Towarzystwo
Hematologów i Transfuzjologów

czcionka: [+] powiększ | [-] pomniejsz

Acta Haematologica Polonica, 2012, 43, 1

Joanna Zaleska · Krzysztof Giannopoulos

Immunotherapeutical approaches for multiple myeloma

Immunoterapia w szpiczaku plazmocytowym

SłOWA KLUCZOWE:
szpiczak plazmocytowyimmunoterapiaantygeny
KEY WORDS:
multiple myeloma (MM)tumor-associated antigens (TAA)immunotherapy
pełna treść »
STRESZCZENIE: Multiple myeloma (MM) is characterized by deep immunodefi ciency
caused by many factors including uncontrolled production of monoclonal
immunoglobulin and inhibitory effect of microenvironment.
Despite the use of different therapeutic strategies as drug treatment,
chemotherapy and stem cell transplantation still remains an incurable
disease. Novel treatment modalities introduced for MM signifi cantly increased
overall survival, but it still reaches not more than 4 years. Therefore
there is a necessity to generate novel therapeutical strategies that
successfully improve quality of MM patients life and cause complete
recovery. Tumor-associated antigens (TAA) are potential targets for cancer
immunotherapy due to their limited expression on normal tissues or
restriction to tumor cells. Epitopes derived from TAA induce specifi c,
cytotoxic T lymphocytes which are able to recognize and eradicate myeloma
cells with good effi cacy. These features allow to construct various
types of peptide-based vaccines, which could prolong MM patients
life and lead to complete remission. In this work we have characterized
(C/T), human telomerase reverse transcriptase (hTERT), X-box binding
protein 1 (XBP-1), PAS domain-containing protein 1 (PASD-1), receptor
for hyaluronic acid–mediated motility (RHAMM), mucin 1 (MUC-1),
Wilms Tumor-1 (WT1), that might represent a target for peptide-based
immunotherapy. Results from fi rst clinical trials on immunotherapy in
MM were also characterized.
SUMMARY: Multiple myeloma (MM) is characterized by deep immunodefi ciency
caused by many factors including uncontrolled production of monoclonal
immunoglobulin and inhibitory effect of microenvironment.
Despite the use of different therapeutic strategies as drug treatment,
chemotherapy and stem cell transplantation still remains an incurable
disease. Novel treatment modalities introduced for MM signifi cantly increased
overall survival, but it still reaches not more than 4 years. Therefore
there is a necessity to generate novel therapeutical strategies that
successfully improve quality of MM patients life and cause complete
recovery. Tumor-associated antigens (TAA) are potential targets for cancer
immunotherapy due to their limited expression on normal tissues or
restriction to tumor cells. Epitopes derived from TAA induce specifi c,
cytotoxic T lymphocytes which are able to recognize and eradicate myeloma
cells with good effi cacy. These features allow to construct various
types of peptide-based vaccines, which could prolong MM patients
life and lead to complete remission. In this work we have characterized
(C/T), human telomerase reverse transcriptase (hTERT), X-box binding
protein 1 (XBP-1), PAS domain-containing protein 1 (PASD-1), receptor
for hyaluronic acid–mediated motility (RHAMM), mucin 1 (MUC-1),
Wilms Tumor-1 (WT1), that might represent a target for peptide-based
immunotherapy. Results from fi rst clinical trials on immunotherapy in
MM were also characterized.

pełna treść:

pobierzpobierz pełną treść publikacji (PDF 149kb)

Pobierz program Adobe Reader®Do otwarcia plików PDF niezbedny jest darmowy program Adobe Reader® Jeśli nie masz tego programu pobierz go tutaj